Patented Ibuprofen, Famotidine Formulation Is Invalid, Panel Affirms
WASHINGTON, D.C. — In a Nov. 16 holding the Federal Circuit U.S. Court of Appeals agreed with a federal judge in Delaware that a generic drug maker was entitled to prevail...To view the full article, register now.
Already a subscriber? Click here to view full article